Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840682 | 1.00 | KDM4E (0.40) | KDM4ERAB9AALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL2837858 | 0.99 | KDM4E (0.39) | KDM4ERAB9AALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL2837850 | 0.99 | KDM4E (0.39) | KDM4ERAB9AALDH1A1POLBTDP1 | |
| SCHEMBL2846949 | 0.84 | LMNA (0.35) | — | |
| SCHEMBL2846952 | 0.84 | LMNA (0.35) | — | |
| SCHEMBL1254769 | 0.81 | BRD4 (0.42) | KDM4ERAB9AALDH1A1POLBTDP1 | |
| SCHEMBL1254770 | 0.81 | BRD4 (0.42) | KDM4ERAB9AALDH1A1POLBTDP1 | |
| SCHEMBL3611131 | 0.80 | RAB9A (0.40) | RAB9A | |
| SCHEMBL3611126 | 0.80 | RAB9A (0.40) | RAB9A | |
| SCHEMBL1253522 | 0.80 | ALDH1A1 (0.45) | KDM4ERAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2687533-B1 | Acrylamide derivatives as FAB I inhibitors | DEBIOPHARM INT SA (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2054422-B1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | DEBIOPHARM INT SA (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2687533-A2 | Acrylamide derivatives as FAB I inhibitors | Affinium Pharmaceuticals, Inc. (CA) | 2014-01-22 | — | — | EP | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-8318720-B2 | Acrylamide derivatives as Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-11-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | KDM4E 3209/4885RAB9A 3088/4885ALDH1A1 2669/4885 |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | KDM4E 4426/4885RAB9A 4245/4885ALDH1A1 1379/4885 |
| US-20100130470-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | KDM4E 4426/4885RAB9A 4245/4885ALDH1A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.